PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-100.00%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-100.00%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
10.60%
EBIT growth 50-75% of CRN.AX's 19.60%. Martin Whitman would suspect suboptimal resource allocation.
10.60%
Positive operating income growth while CRN.AX is negative. John Neff might view this as a competitive edge in operations.
13.84%
Net income growth under 50% of CRN.AX's 47.33%. Michael Burry would suspect the firm is falling well behind a key competitor.
23.33%
EPS growth under 50% of CRN.AX's 47.22%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
23.33%
Diluted EPS growth under 50% of CRN.AX's 47.31%. Michael Burry would worry about an eroding competitive position or excessive dilution.
16.66%
Slight or no buybacks while CRN.AX is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
16.66%
Diluted share change of 16.66% while CRN.AX is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
-46.46%
Negative OCF growth while CRN.AX is at 11374.81%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-93.76%
Negative FCF growth while CRN.AX is at 113.93%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-100.00%
Negative 10Y revenue/share CAGR while CRN.AX stands at 0.00%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-100.00%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-100.00%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
-25.54%
Negative 10Y OCF/share CAGR while CRN.AX stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-25.54%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-25.54%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
26.15%
10Y net income/share CAGR of 26.15% while CRN.AX is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
26.15%
Positive 5Y CAGR while CRN.AX is negative. John Neff might view this as a strong mid-term relative advantage.
26.15%
Positive short-term CAGR while CRN.AX is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.28%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.64%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.
0.06 - 0.07
0.06 - 0.24
1.89M / 3.59M (Avg.)
-1.60 | -0.04